PLATINUM-TITANIUM OXIDE NANOPARTICLES AS A SYNERGISTIC RADIOSENSITIZER AND PHOTOTHERMAL AGENT FOR TREATMENT-RESISTANT GLIOBLASTOMA

Abstract

Glioblastoma is a highly aggressive and treatment-resistant brain tumor characterized by poor prognosis and limited therapeutic success. This study explored the potential of platinum-core titanium oxide-shell nanoparticles as a dual-function therapeutic agent combining radiosensitization and photothermal therapy. Nanoparticles were synthesized using a two-step process and characterized by DLS, zeta potential, XRD, and FTIR analyses, confirming monodisperse, stable, and crystalline core–shell structures. In vitro cytotoxicity was assessed via MTT assay, demonstrating significant dose- and time-dependent reductions in glioblastoma cell viability. Reactive oxygen species (ROS) levels measured by DCFH-DA fluorescence assay indicated nanoparticle-induced oxidative stress, a likely contributor to the observed cytotoxic effects. Furthermore, survival fraction assays incorporating nanoparticle treatment with radiotherapy (2 Gy X-ray) and near-infrared photothermal stimulation revealed a synergistic effect, achieving the greatest reduction in cell survival when all three modalities were combined. Statistical analysis confirmed the significance of these outcomes. These findings underscore the potential of platinum-titanium oxide core–shell nanoparticles as a promising combinational therapy platform for overcoming radioresistance in glioblastoma. The multifunctionality of the nanoplatform, along with its biocompatibility and physicochemical stability, supports its continued development for translational cancer nanomedicine.

View Article